All relevant data, including accession numbers are within the paper and its Supporting Information files.

Introduction {#sec001}
============

*Burkholderia pseudomallei* is a pathogen endemic to Southeast Asia and Northern Australia but is increasingly found in other parts of the world including India, South America, and Africa, where it is naturally found in soil and water \[[@pone.0121052.ref001]\]. The bacterium is the causative agent of melioidosis \[[@pone.0121052.ref002]--[@pone.0121052.ref005]\], a potentially fatal disease in humans. *B*. *pseudomallei* is also considered to be a Tier 1 biothreat agent due to its ease of attainment, ability to cause lethal disease, intrinsic antibiotic resistance \[[@pone.0121052.ref006]\], and lack of a melioidosis vaccine \[[@pone.0121052.ref007]\]. The development of appropriate medical countermeasures against melioidosis has been hampered by access to human patients for clinical trials with compounds that are not currently approved for the treatment of melioidosis. To address this concern, the US Food and Drug Administration (FDA) has instituted the "Animal Rule" 21 CFR that calls for well-characterized strains to be used in animal challenge studies \[[@pone.0121052.ref008]\], including BALB/c mice, which have shown to represent acute human melioidosis \[[@pone.0121052.ref009]\]. Based on several selection criteria, a recent study selected a panel of six *B*. *pseudomallei* strains that would be appropriate for challenge studies under the FDA Animal Rule \[[@pone.0121052.ref007]\].

In the current study, we used whole-genome sequencing (WGS) to genetically characterize a panel of *B*. *pseudomallei* strains to be used as challenge material in therapeutic efficacy studies under the Animal Rule. In addition, we sequenced 5 *B*. *pseudomallei* strains associated with inhalational disease for evaluation as potential challenge strains. The purpose of WGS on these isolates was to (1) characterize the genomic background in each isolate; (2) identify the phylogenetic diversity of panel isolates in the context of a global set of genomes and; (3) identify the distribution of characterized virulence factors for correlation with virulence data obtained in animal challenge studies.

Methods {#sec002}
=======

Strain selection {#sec003}
----------------

Eleven diverse isolates were selected for sequencing ([Table 1](#pone.0121052.t001){ref-type="table"}). Six of these isolates were previously selected as part of a proposed *B*. *pseudomallei* strain panel, based on several selection criteria \[[@pone.0121052.ref007]\]. For five of these isolates, there are finished genome assemblies available in public databases \[[@pone.0121052.ref010]\]; these genomes were sequenced to identify any mutations compared to the published genomes. The genome for an additional isolate, NCTC 13392, has previously been published \[[@pone.0121052.ref011]\]. An additional 5 isolates were selected based on recent isolation and suspected inhalational disease and were associated with acute pneumonia sepsis.

10.1371/journal.pone.0121052.t001

###### Details of isolates sequenced in current study.

![](pone.0121052.t001){#pone.0121052.t001g}

  Isolate                                           Isolation source   Isolation country   Isolation Year   Passages   SRA         Genbank Accession   BEI accession
  ------------------------------------------------- ------------------ ------------------- ---------------- ---------- ----------- ------------------- ---------------
  1106a[\*](#t001fn001){ref-type="table-fn"}        liver abscess      Thailand            1993             10         SRX263957   N/A                 NR-44208
  K96243[\*](#t001fn001){ref-type="table-fn"}       blood              Thailand            1996             22         SRR797065   N/A                 NR-44206
  MSHR305[\*](#t001fn001){ref-type="table-fn"}      brain              Australia           1994             10         SRX263963   N/A                 NR-44225
  MSHR668[\*](#t001fn001){ref-type="table-fn"}      blood              Australia           1995             11         SRX259746   N/A                 NR-44224
  406e[\*](#t001fn001){ref-type="table-fn"}         toe swab           Thailand            1988             10         SRX256398   AQTK00000000        NR-44207
  NCTC 13392[\*](#t001fn001){ref-type="table-fn"}   unknown            Thailand            1996             unknown    SRX245558   AOUG00000000        N/A
  1026b[\*](#t001fn001){ref-type="table-fn"}        blood              Thailand            1993             9          SRX259661   N/A                 NR-9910
  MSHR5855                                          sputum             Australia           2011             7          SRX526461   JMMV00000000        NR-45120
  MSHR5858                                          sputum             Australia           2011             2          SRX264496   AVAK00000000        NR-45120
  HBPUB10134a                                       sputum             Thailand            2010             10         SRR796658   AVAL00000000        NR-44220
  HBPUB10303a                                       sputum             Thailand            2011             10         SRX254948   AVAM00000000        NR-44221

\*genome has been sequenced previously

Animal challenge studies {#sec004}
------------------------

285 BALB/c mice (100% female) were purchased from Charles River Laboratories and were randomly selected and placed into challenge groups (n = 7) based on different isolates and dosing. Mice here housed in Innovive IVC mouse racks using disposable caging (7 mice per cage). Sedated mice were challenged by intranasal inoculation (15 μl per nare) of target doses diluted in Dulbecco's Phosphate-Buffered Saline (PBS); mice were anesthetized intraperitoneally with ketamine (50--120 mg/kg) and xylazine (5--10 mg/kg). Prior to challenge, cultures were grown for 22 hours shaking at 37°C at 250xRPM; no mice were mock-treated in this study. The culture was then centrifuged and re-suspended in PBS containing 0.01% gelatin. The concentration of each challenge dilution was determined by spread plate enumeration.

Following challenge, mice were monitored every 8 hours between days 1 and 7, then twice daily between days 8 and 21; sample HBPUB10303a was only challenged for 14 days due to unforeseen delays in starting the experiment. Observations were made for clinical signs of illness, including respiratory distress, loss of appetite and activity, and seizures; any animal judged to be moribund by a trained animal technician was humanely euthanized. All study survivors were humanely euthanized with CO~2~ inhalation on Study Day 21. Kaplan-Meier survival curves were created using the 'survival' package in R \[[@pone.0121052.ref012]\]. Animal challenge studies were conducted at the Battelle Biomedical Research Center (BBRC). All animal work was approved by Battelle's IACUC prior to study initiation.

DNA extraction, library creation, sequencing {#sec005}
--------------------------------------------

DNA library constructions were performed using the KAPA Library Preparation Kits with Standard PCR Library Amplification/Illumina series (KAPA biosystems, Boston MA, code KK8201). Quality and quantity of genomic DNA were evaluated by agarose gel analysis. One to two micrograms of DNA per sample were fragmented using a SonicMan (Matrical) with following parameters: 75.0 seconds pre chill, 16 cycles, 10.0 sec sonication, 100% power, 75.0 sec lid chill, 10.0 sec plate chill, and 75.0 sec post chill. The fragmented DNA was purified using QIAGEN QIAquick PCR purification columns (QIAGEN, cat. no. 28104) and eluted into 42.5 μl of Elution Buffer. The adapter ligation used 1.5 μl of the 40 μM adapter oligo mix \[[@pone.0121052.ref013]\]. Only one post-ligation bead cleanup was done. All purification steps were done with the 1.8x SPRI bead protocol in the KAPA protocol. Size selection of fragments was gel based; 30 μl of clean ligated material was run onto a 2% agarose gel. Several gel slices, corresponding to different average DNA fragment sizes (300, 600, and 1000bp fragments) were extracted from the gel and purified with a QIAGEN Gel Extraction kit (QIAGEN, cat. no. 28704) and eluted in 30 μl of Elution Buffer. Due to the high GC content of the samples, the PCR was optimized to improve yield and genomic coverage. Two microliters of DNA, 2 μl of 10 μM of both primers, 25 μl of NEBNext High-Fidelity 2X PCR Master Mix (New England Biolabs, Ipswich, MA, cat. no. M0541S), and 22 μl of 5 M Betaine (Sigma-Aldrich, St. Louis, MO, cat. no. B0300-1VL) were combined. The following PCR parameters were used: initial denaturation of 2 min at 98°C, 12 cycles of 30 sec at 98°C, 20 sec at 65°C, 30 sec at 72°C, with a final extension of 5 min at 72°C.

Genome assembly {#sec006}
---------------

For strains that have been sequenced previously, a comparative assembly approach was employed. Reads were assembled against the reference genome ([S1 Table](#pone.0121052.s005){ref-type="supplementary-material"}) with AMOScmp \[[@pone.0121052.ref014]\]. Assembled contigs were then aligned against the reference genome with ABACAS \[[@pone.0121052.ref015]\] to obtain a genomic scaffold. Gaps in scaffolds were filled with IMAGE \[[@pone.0121052.ref016]\], which also splits un-filled scaffolds into contigs. In addition to the comparative assembly, reads were also assembled with Abyss v. 1.3.4 \[[@pone.0121052.ref017]\]. The two assemblies were aligned with Mugsy \[[@pone.0121052.ref018]\] and regions specific to the *de novo* assembly were parsed from the MAF file \[[@pone.0121052.ref019]\], as has been done previously \[[@pone.0121052.ref020]\]. Putative unique regions in the *de novo* assembly were aligned against the comparative assembly with BLASTN \[[@pone.0121052.ref021]\]. Regions that significantly aligned (\>90% ID, \>90% query length) to the comparative assembly were filtered from the analysis. Remaining regions were combined with the comparative assembly. Assembly errors were corrected from this concatenated assembly with iCORN \[[@pone.0121052.ref022]\], using ten iterations. For strains that had not been sequenced previously, genomes were assembled *de novo* with Abyss v 1.3.4 and assembly errors were corrected with iCORN. Assembly details are shown in [S1 Table](#pone.0121052.s005){ref-type="supplementary-material"}.

*In silico* multi-locus sequence typing (*is*MLST) {#sec007}
--------------------------------------------------

BLASTN \[[@pone.0121052.ref021]\] was used to extract sequences from the seven loci in the *B*. *pseudomallei* MLST scheme \[[@pone.0121052.ref023]\] from all genome assemblies. To be considered a match, the alignment from the query genome must match a reference allele 100%. Sequence types were assigned to genomes when exact profile matches were identified. The *is*MLST functionality was performed with a custom Python script (<https://gist.github.com/jasonsahl/33b0d9a8e3ac035bb92c>). MLST typing information is shown in [S1 Table](#pone.0121052.s005){ref-type="supplementary-material"}.

Single nucleotide polymorphism (SNP) and indel identification and annotation {#sec008}
----------------------------------------------------------------------------

For re-sequencing efforts ([Table 1](#pone.0121052.t001){ref-type="table"}), raw reads were mapped to the finished genome with BWA-MEM v0.7.5 \[[@pone.0121052.ref024]\]. SNPs and indels were then called with the UnifiedGenotyper in GATK v. 2.7 \[[@pone.0121052.ref025]\]; nucmer \[[@pone.0121052.ref026]\] was used to find duplicate regions in the reference genome and any SNPs falling within duplicate regions were filtered from the analysis. For a SNP or indel to be called, we required a minimum coverage of 6x and a minimum proportion threshold of 0.90. Nucleotide variants were annotated with snpEFF \[[@pone.0121052.ref027]\]. All variants were visually confirmed from BAM files with Tablet \[[@pone.0121052.ref028]\].

Synteny between previously sequenced genomes {#sec009}
--------------------------------------------

In addition to identifying variants between finished genomes and re-sequencing projects, genome assemblies were aligned to completed genomes with MUMmer \[[@pone.0121052.ref029]\] and dot plots were visualized with mummerplot to identify any structural variation.

Core genome SNP phylogeny {#sec010}
-------------------------

To visualize the phylogenetic diversity of genomes sequenced in this study, a core genome phylogenetic approach was employed; core regions are defined as sequence conserved in all examined genomes. A diverse set of finished and draft genomes was compiled ([S2 Table](#pone.0121052.s006){ref-type="supplementary-material"}). Raw reads were mapped to *B*. *pseudomallei* K96243 \[[@pone.0121052.ref030]\] with BWA-MEM \[[@pone.0121052.ref024]\]. SNPs were called from each BAM file with GATK, using the EMIT_ALL_CONFIDENT_SITES method, with a minimum coverage of 6x and a minimum proportion of 0.90. For genomic assemblies, SNPs were identified from nucmer alignments. Positions in K96243 were directly mapped to the corresponding position in each query genome assembly. A matrix was generated ([S1 Dataset](#pone.0121052.s001){ref-type="supplementary-material"}) with NASP (<http://tgennorth.github.io/NASP/>) from all reference positions called and polymorphic sites were identified. SNPs that could not be called by GATK, or failed to pass the depth or proportion filters, were filtered from the matrix, as well as SNPs that fell within identified duplications. The remaining dataset consisted of 62,663 SNPs, 50,290 of them being informative. A maximum likelihood phylogeny was inferred on this dataset with RAxML v8.0.17 \[[@pone.0121052.ref031], [@pone.0121052.ref032]\] using the ASC_GTRGAMMA model and 100 bootstrap replicates. The retention index (RI) value \[[@pone.0121052.ref033]\] was calculated with Phangorn \[[@pone.0121052.ref034]\].

SNP and homoplasy density {#sec011}
-------------------------

To identify the conservation of the reference chromosomes, as well as to potentially identify any lateral gene transfer events that may confound the phylogeny, a SNP density (SD) and homoplasy density (HD) approach was employed. The SNP matrix was parsed over 1-kb non-overlapping windows of each chromosome and the number of informative SNPs was then calculated. The dataset was then processed with Paup v4.0b10 \[[@pone.0121052.ref035]\] to calculate the retention index (RI) value for each SNP. An RI value \< 0.5 was considered to be homoplasious and the number of homoplasious SNPs over the same 1-kb window was then calculated. The HD value for each 1-kb window was calculated by dividing the number of homoplasious SNPs by the total number of informative SNPs. The distribution of SD and HD across the two chromosomes in K96243 was visualized with Circos \[[@pone.0121052.ref036]\].

*In silico* gene screen {#sec012}
-----------------------

A set of previously described virulence factors \[[@pone.0121052.ref001], [@pone.0121052.ref030], [@pone.0121052.ref037]--[@pone.0121052.ref042]\] characterized in *B*. *pseudomallei* were compiled ([S3 Table](#pone.0121052.s007){ref-type="supplementary-material"}). Genes were screened against the genomes sequenced in this study with a large-scale blast score ratio (LS-BSR) approach \[[@pone.0121052.ref043]\]. Genes were translated with BioPython ([www.biopython.org](http://www.biopython.org)) and aligned against its nucleotide sequence with TBLASTN in order to obtain the maximum alignment (reference) bit score. Each gene was then aligned against each genome with TBLASTN in order to obtain the query alignment bit score. The BSR \[[@pone.0121052.ref044]\] was obtained by dividing the reference bit score by the query bit score. Genes with a BSR value \> 0.90 or \< 0.80 in all genomes were removed from the analysis; the complete LS-BSR matrix is available as [S2 Dataset](#pone.0121052.s002){ref-type="supplementary-material"}. The genes were then correlated with the tree to identify phylogenetic patterns of gene presence/absence.

Genotype and phenotype correlations {#sec013}
-----------------------------------

Two approaches were performed to determine if there were correlations between genomic information and survival information obtained from animal challenge studies. The survival data were split into three categories: low virulence (100% mouse survival after 21 days), intermediate virulence (\<100%, \>0% survival after 21 days), and high virulence (0% mouse survival after 21 days). LS-BSR values across all genomes were multiplied by 100 in order to convert all float values to integers. The adjusted LS-BSR values were then correlated with the categorical virulence data using a Kruskal-Wallis test \[[@pone.0121052.ref045]\] implemented in QIIME v. 1.8.0 \[[@pone.0121052.ref046]\]. Core genome SNP data were also correlated to categorical data with a chi-square test implemented in SciPy. P-values were corrected with the Benjamini-Hochberg correction \[[@pone.0121052.ref047]\]. To test for false positives, genomes were randomly assigned to two groups of equal size and the average number of SNPs unique to each group was calculated over 10 iterations.

Unique genomic regions {#sec014}
----------------------

In addition to screening characterized virulence genes in assembled genomes, a *de novo* approach was also performed. All coding regions (CDSs) from all genomes in the phylogeny were compared with LS-BSR. Regions were determined to be unique to a given genome if they contained a BSR \< 0.4 in all non-targeted genomes. Each unique CDS was then aligned against the GenBank \[[@pone.0121052.ref048]\] nucleotide database with BLASTN, and the closest hit, based on highest bit score, was identified.

Ethics Statement {#sec015}
----------------

The animal protocol (2934--100007643) was approved by the Battelle Institutional Animal Care and Use Committee. The research was conducted in compliance with the Animal Welfare Act and followed the principles in the Guide for the Care and Use of Laboratory Animals from the National Research Council, Office of Laboratory Animal Welfare (OLAW), and USDA. Additionally, the research was conducted following an Institutional Animal Care and Use Committee (IACUC) approved protocol. The institution where the research was conducted is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

Results {#sec016}
=======

Comparisons of re-sequenced isolates with finished genomes {#sec017}
----------------------------------------------------------

Five of the genomes sequenced in this study represent re-sequencing projects of finished genomes available in public databases ([S1 Table](#pone.0121052.s005){ref-type="supplementary-material"}). However, due to standard laboratory passages, new nucleotide variants can accumulate \[[@pone.0121052.ref049]\], and were identified in the current study using raw read data. The results demonstrate that many re-sequenced isolates show little mutation since the genomes were published ([Table 2](#pone.0121052.t002){ref-type="table"}). However, the version of K96243 that was sequenced in the current study showed numerous variant positions (33) compared to the completed genome ([Table 2](#pone.0121052.t002){ref-type="table"}), including the loss of two annotated stop codons. Some of these differences could be errors in the original genome sequence, which we are unable to verify. In addition to the analysis of nucleotide variants, the synteny of genomes was visualized as dot plots ([S1 Fig](#pone.0121052.s003){ref-type="supplementary-material"}) and demonstrated high synteny between all re-sequenced genome assemblies and finished genomes.

10.1371/journal.pone.0121052.t002

###### Nucleotide variant information for re-sequencing projects conducted in current study.

![](pone.0121052.t002){#pone.0121052.t002g}

  Name     Chromosome    Coordinate   Reference   Query   Locus             Effect                 Annotation                             Proportion   Depth
  -------- ------------- ------------ ----------- ------- ----------------- ---------------------- -------------------------------------- ------------ -------
  K96243   NC006350.1    549058       G           A       BPSL0500          non-synonymous         hexosaminidase                         0.99         165
  K96243   NC006350.1    549059       T           G       BPSL0500          synonymous             hexosaminidase                         1.00         163
  K96243   NC006350.1    549061       C           T       BPSL0500          non-synonymous         hexosaminidase                         1.00         162
  K96243   NC006350.1    549062       C           T       BPSL0500          synonymous             hexosaminidase                         1.00         165
  K96243   NC006350.1    2399742      C           G       BPSL2010          non-synonymous         lipid metabolism-like protein          0.99         138
  K96243   NC006350.1    2399743      C           G       BPSL2010          non-synonymous         lipid metabolism-like protein          0.99         140
  K96243   NC006351.1    1607761      T           C       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   1.00         8
  K96243   NC006351.1    1607796      G           C       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   0.98         100
  K96243   NC006351.1    1607820      G           C       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   0.99         99
  K96243   NC006351.1    1607822      G           C       BPSS1194          synonymous             peptide synthase/polyketide synthase   0.99         99
  K96243   NC006351.1    1607825      G           C       BPSS1194          synonymous             peptide synthase/polyketide synthase   0.97         102
  K96243   NC006351.1    1607838      T           G       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   0.99         117
  K96243   NC006351.1    1607851      T           C       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   0.99         111
  K96243   NC006351.1    1607874      G           T       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   0.97         62
  K96243   NC006351.1    1607887      G           C       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   1.00         58
  K96243   NC006351.1    1607894      G           A       BPSS1194          synonymous             peptide synthase/polyketide synthase   0.99         72
  K96243   NC006351.1    1607902      G           C       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   1.00         68
  K96243   NC006351.1    1607910      C           A       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   0.95         57
  K96243   NC006351.1    1607917      G           C       BPSS1194          non-synonymous         peptide synthase/polyketide synthase   1.00         48
  K96243   NC006351.1    1607997      C           A       intergenic        N/A                    N/A                                    0.96         49
  K96243   NC006351.1    1608005      T           C       BPSS1195          stop codon destroyed   non-ribosomal peptide synthase         1.00         53
  K96243   NC006351.1    1608012      G           C       BPSS1195          non-synonymous         non-ribosomal peptide synthase         0.98         55
  K96243   NC006351.1    1608015      G           T       BPSS1195          non-synonymous         non-ribosomal peptide synthase         1.00         55
  K96243   NC006351.1    1608017      T           A       BPSS1195          non-synonymous         non-ribosomal peptide synthase         1.00         55
  K96243   NC006351.1    1608029      G           C       BPSS1195          synonymous             non-ribosomal peptide synthase         1.00         98
  K96243   NC006351.1    1615675      C           T       BPSS1197          non-synonymous         BPSS1197                               0.98         192
  K96243   NC006351.1    1764438      G           T       intergenic        N/A                    N/A                                    1.00         96
  K96243   NC006351.1    1764448      G           T       intergenic        N/A                    N/A                                    0.93         101
  K96243   NC006351.1    2337386      A           C       BPSS1703          stop codon destroyed   hypothetical protein                   1.00         188
  1106a    NC_009076.1   797819       T           G       BURPS1106A_0812   non-synonymous         sensor histidine kinase                0.99         125
  1026b    NC_017832.1   2020919      G           A       BP1026B_II1596    non-synonymous         type VI secretion system, VGR          0.91         297
  668      NC_009074.1   3755785      G           C       BURPS668_3852     synonymous             chemotaxis protein methyltransferase   0.99         289
  668      NC_009075.1   92668        CG          C       intergenic        N/A                    N/A                                    0.91         276

Core genome single nucleotide polymorphism (SNP) phylogeny {#sec018}
----------------------------------------------------------

To phylogenetically characterize the isolates sequenced in this study, a maximum likelihood phylogeny was inferred from \~63,000 core genome SNPs ([Fig. 1](#pone.0121052.g001){ref-type="fig"}) identified from 44 genomes. The results demonstrate that the isolates sequenced in the current study show a broad phylogenetic history compared to previously sequenced isolates. By including phylogenetically diverse isolates in the isolate panel, local patterns of gene distribution do not bias the analysis. The retention index (RI) value of the data and maximum likelihood phylogeny demonstrated signs of homoplasy (RI = 0.62). Recombination in *B*. *pseudomallei* has been previously described \[[@pone.0121052.ref023]\] and homoplasy was anticipated due the recombinatorial nature of the species.

![A maximum likelihood phylogeny inferred from a concatenation of \~63,000 core-genome single nucleotide polymorphisms (SNPs) identified in the eleven genomes sequenced in this study, shown in red, and a reference set of genomes ([S2 Table](#pone.0121052.s006){ref-type="supplementary-material"}).\
The tree was inferred with RAxML v8 \[[@pone.0121052.ref031], [@pone.0121052.ref032]\] using the ASC_GTRGAMMA model and 100 bootstrap replicates. Filled circles are placed at nodes where the bootstrap support values are \>90%.](pone.0121052.g001){#pone.0121052.g001}

SNP and homoplasy density {#sec019}
-------------------------

The RI value of the phylogeny demonstrated the presence of homoplasy. Based on this dataset, the presence of homoplasy across the reference genome, K96243, was investigated with a SNP and homoplasy density approach. The results demonstrate that with the isolates tested, chromosome 1 of *B*. *pseudomallei* K96243 is more highly conserved than chromosome 2 ([Fig. 2](#pone.0121052.g002){ref-type="fig"}). Additionally, the homoplasy is distributed across both chromosomes, with no clear regions associated with specific recombination or lateral gene transfer events.

![Plots of single nucleotide polymorphism (SNP) density and homoplasy density (HD), across the two chromosomes of the reference isolate, K96243 \[[@pone.0121052.ref030]\].\
The outer ring represents the number of informative SNPs across 1-kb genomic intervals. The inner ring indicates the number of homoplasious SNPs, as determined by a retention index (RI) value \<0.5 calculated by Paup \[[@pone.0121052.ref035]\], divided by the total number of informative SNPs over the same 1-kb genomic interval. HD and SD values were visualized with Circos \[[@pone.0121052.ref036]\].](pone.0121052.g002){#pone.0121052.g002}

Unique coding sequences (CDSs) {#sec020}
------------------------------

*B*. *pseudomallei* has a highly plastic genome and has the ability to acquire new genes horizontally from other microorganisms, especially as the pathogen persists in the environment. A large-scale blast score ratio (LS-BSR) analysis was performed on the 44 *B*. *pseudomallei* genomes in the phylogeny ([Fig. 1](#pone.0121052.g001){ref-type="fig"}) to identify any unique CDSs in the 11 isolates sequenced in the current study; the criteria for a CDS to be considered unique is that it must have a BSR value \< 0.4 in all non-targeted genomes. A list of closest BLAST hits to unique CDSs not associated with either *B*. *pseudomallei* or *B*. *mallei*, based on the highest bit score, is shown in [Table 3](#pone.0121052.t003){ref-type="table"}. These regions are likely associated with genomic islands horizontally transferred from related organisms \[[@pone.0121052.ref050]\].

10.1371/journal.pone.0121052.t003

###### Annotation for unique genes identified in genomes sequenced in the current study.

![](pone.0121052.t003){#pone.0121052.t003g}

  Genome        closest BLAST match   closest BLAST annotation                   nearest BLAST organism                    protein ID (%)   query length
  ------------- --------------------- ------------------------------------------ ----------------------------------------- ---------------- --------------
  MSHR5858      BUPH_05469            integrase catalytic subunit                *Burkholderia phenoliruptrix*             99               99
  NCTC13392     BDB_110343            hypothetical                               blood disease bacterium R229              83               99
  NCTC13392     BDB_110341            hypothetical                               blood disease bacterium R229              82               98
  10134a        YP_582472             tyrosine-based site-specific recombinase   *Cupriavidus metallidurans* CH34          64               98
  10134a        YP_005995055          hypothetical                               *Ralstonia solanacearum* CMR15            62               98
  10134a        YP_005995053          putative integrase                         *Ralstonia solanacearum* CMR15            49               98
  10134a        WP_017232947          hypothetical                               *Pandoraea* sp. B-6\]                     91               99
  10134a        WP_017232948          DEAD/DEAH box helicase                     *Pandoraea* sp. B-6\]                     91               100
  10134a        WP_008918033          N-6 DNA methylase                          *Burkholderia* sp. H160                   78               99
  10134a        WP_017232950          ATP-dependent helicase                     *Pandoraea* sp. B-6\]                     87               99
  10134a        WP_006395564          hypothetical                               *Achromobacter xylosoxidans*              60               83
  HBPUB10303a   YP_443256             type I restriction-modification system     *Burkholderia thailandensis* E264         78               72
  HBPUB10303a   YP_443255             hypothetical                               *Burkholderia thailandensis* E264         91               99
  HBPUB10303a   YP_005028223          hypothetical                               *Dechlorosoma suillum* PS                 74               99
  HBPUB10303a   WP_008248767          hypothetical                               *Limnobacter* sp. MED105                  51               99
  HBPUB10303a   YP_006030638          helicase domain-containing protein         *Ralstonia solanacearum* Po82             79               99
  MSHR5855      Bamb_2400             phage integrase family protein             *Burkholderia ambifaria* AMMD             89               96
  MSHR5855      BTQ_1983              putative membrane proten                   *Burkholderia thailandensis* 2002721723   99               100
  MSHR5855      BTJ_373               hypothetical                               *Burkholderia thailandensis* E444         99               100
  MSHR5855      bglu_1g24070          hypothetical                               *Burkholderia glumae* BGR1                91               99
  MSHR5855      BTI_1944              hypothetical                               *Burkholderia thailandensis* MSMB121      99               100
  MSHR5855      BTI_1943              hypothetical                               *Burkholderia thailandensis* MSMB121      78               100
  MSHR5855      BTI_1942              helix-turn-helix family protein            *Burkholderia thailandensis* MSMB121      99               100
  MSHR5855      Rpic12D_1056          lipoprotein releasing system               *Ralstonia pickettii* 12D                 98               100

Virulence gene profile {#sec021}
----------------------

A comprehensive set of virulence-associated genes ([S3 Table](#pone.0121052.s007){ref-type="supplementary-material"}) was screened against the 11 genomes sequenced in this study with LS-BSR. To only compare differentially conserved regions, genes were filtered if they had a BSR value \> 0.90 in all 11 genomes. The resulting variable set of genes (n = 54) was correlated to the phylogeny and LS-BSR values were visualized as a heatmap ([Fig. 3](#pone.0121052.g003){ref-type="fig"}). The results demonstrate that phylogenetically-distinct isolates contain a variable composition of virulence-associated genes.

![A heatmap of blast score ratio (BSR) values \[[@pone.0121052.ref044]\] calculated from a known set of virulence factors characterized in *B*. *pseudomallei* ([S3 Table](#pone.0121052.s007){ref-type="supplementary-material"}) with the large-scale blast score ratio (LS-BSR) pipeline \[[@pone.0121052.ref043]\].\
A maximum likelihood phylogeny was inferred on a concatenation of single nucleotide polymorphisms (SNPs) and was correlated to the heatmap.](pone.0121052.g003){#pone.0121052.g003}

Every *B*. *pseudomallei* isolate in this study contained the *B*. *pseudomallei bimA* (BimA~Bp~) allele \[[@pone.0121052.ref051]\], except *B*. *pseudomallei* MSHR668, which contained the alternative *B*. *mallei*-type (BimA~Bm~). The most severe clinical presentations have been associated with the co-occurrence of BimA~Bm~ with another virulence-associated gene, filamentous hemagglutinin *fhaB3* (BPSS2053 in *B*. *pseudomallei* K96243), which is linked with adhesion and heightened virulence \[[@pone.0121052.ref052], [@pone.0121052.ref053]\]. While *B*. *pseudomallei* MSHR668 is missing *fhaB3*, it does contain another *fhaB* gene (similar to *fhaB1* from *B*. *pseudomallei* MSHR305 \[[@pone.0121052.ref054]\]). *fhaB3* was observed in all Asian isolates in this study, which is consistent with previous work \[[@pone.0121052.ref054], [@pone.0121052.ref055]\]. Isolates sequenced in this study either contained the *Yersinia*-like fimbriae cluster (YLF) or the *B*. *thailandensis*-like flagellum and chemotaxis (BTFC) gene cluster. These genes were included in our analysis because they are suggested as being active during melioidosis.

Two isolates in this study, 1026b and MSHR305, exhibited reduced sequence homology to the T6SS-1 gene, BPSS1511. The T6SS-1 representative sequence, *icmF* gene (BPSS1511), which is required for intracellular growth of many pathogens associated with eukaryotic cells \[[@pone.0121052.ref056]\], showed homology, but lower sequence identity, in 1026b and MSHR305. Four isolates (MSHR5855, MSHR305, 1106a, and HBPUB10134a) exhibited reduced sequence homology for BPSS1493, a hypothetical protein associated with type VI secretion.

Animal challenge studies {#sec022}
------------------------

To identify differential virulence between ten of the eleven isolates sequenced in this study, BALB/c mice (seven per group) were challenged at different concentrations of inoculum ([Table 4](#pone.0121052.t004){ref-type="table"}). At an average of \~10 colony forming units (CFUs) per group, four of the ten isolates killed all of the mice in the group, 5 of the isolates killed an intermediate number of mice, and one isolate (1106a) killed none of the mice ([Table 4](#pone.0121052.t004){ref-type="table"}, [S2 Fig](#pone.0121052.s004){ref-type="supplementary-material"}, [S4 Table](#pone.0121052.s008){ref-type="supplementary-material"}); HBPUB10303a was treated as intermediate in terms of virulence, despite the fact that the isolate was challenged for only 14 days instead of 21 in this experiment. At a high concentration of inoculum (\~12,000 CFUs), none of the mice survived when challenged with any of the ten panel isolates. This demonstrates that all of the isolates are virulent by intranasal inoculation, but there is a dose-dependent virulence response.

10.1371/journal.pone.0121052.t004

###### Survival data of 10 strains injected intranasally in BALB/c mice.

![](pone.0121052.t004){#pone.0121052.t004g}

  Challenge Strain   Target CFU:10   Target CFU: 100   Target CFU: 1000   Target CFU: 10000                                        
  ------------------ --------------- ----------------- ------------------ ------------------- -------------- ---- ---------------- ---
  K96243             13(+/-0)        57                170(+/-21)         14                  1581(+/-212)   0    11940(+/-1485)   0
  MSHR406e           13(+/-0)        0                 135(+/-4)          0                   1365(+/-106)   0    12840(+/-636)    0
  1026b              12(+/-0)        57                127(+/-11)         0                   1215(+/-106)   0    11355(+/-785)    0
  1106a              12(+/-0)        100               128(+/-23)         71                  1220(+/-112)   29   12090(+/-2121)   0
  MSHR305            16(+/-1)        29                149(+/-15)         0                   1524(+/-21)    0    14100(+/-2121)   0
  MSHR668            14(+/-0)        0                 122(+/-2)          0                   1095(+/-8)     0    12945(+/-912)    0
  MSHR5855           16(+/-1)        0                 185(+/-48)         0                   1575(+/-136)   0    14550(+/-933)    0
  MSHR5858           14(+/-2)        86                154(+/-8)          14                  1485(+/-119)   0    15750(+/-2630)   0
  HBPUB10303a        6(+/-0)         71                59(+/-1)           14                  537(+/-38)     0    5280(+/-424)     0
  HBPUB10134a        16              0                 163                0                   1779           0    18810            0

Genotype and phenotype correlations {#sec023}
-----------------------------------

Differences were observed in both the virulence gene profile and the animal challenge studies. To identify if any CDSs were associated with differential virulence, a combined LS-BSR/QIIME analysis was performed. A Kruskal-Wallis test \[[@pone.0121052.ref045]\] demonstrated that numerous CDSs were significantly (false detection rate adjusted (FDR) p\<0.05) differentially conserved between groups ([Table 5](#pone.0121052.t005){ref-type="table"}); three of these CDSs (BPSS0771, BPSS1185, BPSS1269) have previously been associated with virulence ([Table 5](#pone.0121052.t005){ref-type="table"}). Additionally, an association was made between core genome SNPs and differential virulence. Forty SNPs were only identified in high virulence isolates ([Table 6](#pone.0121052.t006){ref-type="table"}), which could be due to descent and subsequent loss by intermediate and low virulence isolates, but may also be associated with convergent evolution and virulence ([Fig. 3](#pone.0121052.g003){ref-type="fig"}). By randomly assigning genomes to high and low virulence groups, an average of 31 correlated SNPs were identified over ten iterations. This demonstrates that with small sample sets, identified correlations would definitely need to be corroborated with functional characterization.

10.1371/journal.pone.0121052.t005

###### Correlations of LS-BSR values with observed differential virulence in BALB/c mice.

![](pone.0121052.t005){#pone.0121052.t005g}

  Accession   Annotation                             BSR average (high)[\*](#t005fn001){ref-type="table-fn"}   BSR average (intermediate)[\*](#t005fn001){ref-type="table-fn"}   BSR average (low)[\*](#t005fn001){ref-type="table-fn"}   FDR p-value
  ----------- -------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------------------------- -------------
  BPSS1185    undefined product                      73.5                                                      87.2                                                              14                                                       0.0000
  BPSL2990    histone H1-like protein                100                                                       71                                                                41                                                       0.0003
  BPSL0016    general secretory pathway protein L    100                                                       99.8                                                              51                                                       0.0022
  BDL_4286    response regulator                     97.25                                                     87.2                                                              49                                                       0.0082
  BPSS1308    isoaspartyl peptidase                  100                                                       99.6                                                              54                                                       0.0082
  BPSL0859    N-acetylmuramoyl-L-alanine amidase     100                                                       100                                                               55                                                       0.0106
  BPSS0771    hypothetical protein                   98                                                        81.6                                                              50                                                       0.0147
  BPSS1269    peptide_synthase/polyketide_synthase   87.75                                                     99.2                                                              54                                                       0.0324
  BPSS1212    hypothetical protein                   99.75                                                     78.4                                                              54                                                       0.0454

\*High, intermediate and low virulence determined by intranasal challenge at \~10 colony forming units.

10.1371/journal.pone.0121052.t006

###### Single nucleotide polymorphisms (SNPs) unique to high virulence isolates.

![](pone.0121052.t006){#pone.0121052.t006g}

  Chrom         Coordinate   K96243 call   query call   refAA   derivedAA   locus tag    Annotation
  ------------- ------------ ------------- ------------ ------- ----------- ------------ ----------------------------------------------
  NC_006350.1   220073       C             T            R       Q           BPSL0211     lipid A biosynthesis lauroyl acyltransferase
  NC_006350.1   220163       C             T            R       Q           BPSL0211     lipid A biosynthesis lauroyl acyltransferase
  NC_006350.1   240744       T             C            M       V           BPSL0230     fliF; flagellar MS-ring protein
  NC_006350.1   534205       G             T            A       D           BPSL0492     hypothetical protein
  NC_006350.1   554241       T             C            A       A           BPSL0504     rpoH; RNA polymerase factor sigma-32
  NC_006350.1   1839157      C             G            N/A     N/A         intergenic   N/A
  NC_006350.1   1839166      G             A            N/A     N/A         intergenic   N/A
  NC_006350.1   1839172      T             C            N/A     N/A         intergenic   N/A
  NC_006350.1   1839197      A             C            N/A     N/A         intergenic   N/A
  NC_006350.1   1839256      A             G            N/A     N/A         intergenic   N/A
  NC_006350.1   1839334      C             T            N/A     N/A         intergenic   N/A
  NC_006350.1   1839988      T             C            K       R           BPSL1583     hypothetical protein
  NC_006350.1   1840050      G             A            A       A           BPSL1583     hypothetical protein
  NC_006350.1   2402720      T             C            N/A     N/A         intergenic   N/A
  NC_006350.1   2440328      A             G            D       D           BPSL2041     hypothetical protein
  NC_006350.1   2553415      C             G            A       A           BPSL2126     transport-related, membrane protein
  NC_006350.1   2555149      G             A            N/A     N/A         intergenic   N/A
  NC_006350.1   2555151      C             T            N/A     N/A         intergenic   N/A
  NC_006350.1   2820597      A             G            I       T           BPSL2334     hypothetical protein
  NC_006350.1   2847891      T             C            N/A     N/A         intergenic   N/A
  NC_006350.1   3021077      A             C            N/A     N/A         intergenic   N/A
  NC_006350.1   3403668      G             T            T       T           BPSL2842     FAD-binding oxidase
  NC_006350.1   3654489      C             G            N/A     N/A         intergenic   N/A
  NC_006350.1   3924581      G             A            H       H           BPSL3305     cheW; chemotaxis protein
  NC_006350.1   4073158      T             C            E       G           BPSL3430     glutamine amidotransferase
  NC_006351.1   702758       G             A            G       S           BPSS0515     hypothetical protein
  NC_006351.1   1236140      T             G            P       P           BPSS0936     hypothetical protein
  NC_006351.1   1269935      T             C            N/A     N/A         intergenic   N/A
  NC_006351.1   1398575      C             T            P       P           BPSS1026     hypothetical protein
  NC_006351.1   1398581      A             G            \*      W           BPSS1026     hypothetical protein
  NC_006351.1   1917766      T             C            N/A     N/A         intergenic   N/A
  NC_006351.1   2455301      T             G            S       A           BPSS1795     hypothetical protein
  NC_006351.1   2514965      G             A            N/A     N/A         intergenic   N/A
  NC_006351.1   2695450      C             T            N/A     N/A         intergenic   N/A
  NC_006351.1   3000485      G             A            N/A     N/A         intergenic   N/A
  NC_006351.1   3042744      A             G            D       D           BPSS2265     monooxygenase
  NC_006351.1   3097464      G             A            N/A     N/A         intergenic   N/A
  NC_006351.1   3097471      C             T            N/A     N/A         intergenic   N/A
  NC_006351.1   3097776      C             A            N/A     N/A         intergenic   N/A
  NC_006351.1   3160929      G             A            N/A     N/A         intergenic   N/A

Discussion {#sec024}
==========

*Burkholderia pseudomallei* is an important pathogen as both the causative agent of melioidosis and as a potential biothreat agent. In the development of medical countermeasures against melioidosis, a panel of clinically relevant isolates have been identified \[[@pone.0121052.ref007]\] for challenge studies under the FDA Animal Rule \[[@pone.0121052.ref008]\]. In this study, we sequenced all 6 of these isolates as well as 5 additional isolates associated with human inhalational melioidosis. A comparative genomics approach was employed to understand the genetic composition of each genome and the distribution of genetic elements between genomes. These results were correlated with animal survival data to determine if phenotype/genotype correlations could be identified.

Ten of the 11 isolates were passed through a BALB/c mouse model in groups of seven mice per isolate. Differential virulence was observed between isolates, with MSHR668 demonstrating the highest virulence ([S2 Fig](#pone.0121052.s004){ref-type="supplementary-material"}, [Table 2](#pone.0121052.t002){ref-type="table"}), based on time to death. An attempt was made to correlate both the distribution of coding sequences (CDSs), based on large-scale blast score ratio (LS-BSR) values, and single nucleotide polymorphisms (SNPs), with differential virulence. Three CDSs previously associated with virulence were differentially conserved between disease severity groups ([Table 4](#pone.0121052.t004){ref-type="table"}). Additionally, SNPs were identified that were only present in high-virulence isolates ([Table 6](#pone.0121052.t006){ref-type="table"}). While the limited number of isolates tested in this study precludes definitive correlations between genotype and phenotype, differentially conserved CDSs and/or SNPs may inform larger-scale targeted functional studies, which may help to better understand the pathogenesis of *B*. *pseudomallei*, and subsequently, may improve human health.

A maximum likelihood phylogeny inferred from a concatenation of \~60,000 core-genome SNPs demonstrated that the eleven isolates sequenced in the current study represent broad phylogenetic diversity. The retention index (RI) value, which provides a representation of the homoplasy in the dataset, demonstrated signs of homoplasy, which can confound accurate phylogenetic reconstruction. Plotting the observed homoplasy density (HD) across both chromosomes of *B*. *pseudomallei* K96243 demonstrated that the homoplasy was evenly distributed, with no isolated regions of recombination in the core genome. Although this underlying homoplasy may confound phylogenetic relationships, especially in deeply branching nodes, the phylogeny still demonstrates the overall diversity of the eleven isolates sequenced in the current study.

Differences in the distribution of virulence-associated genes were observed based a LS-BSR analysis. One clear difference was the presence of the *B*. *mallei bimA* (*BimA* ~Bm~) allele in MSHR668 and the *B*. *pseudomallei* version (*BimA* ~Bp~) in all other isolates ([Fig. 3](#pone.0121052.g003){ref-type="fig"}). In previous studies, 12% of Australian isolates contained *BimA* ~Bm~ \[[@pone.0121052.ref055], [@pone.0121052.ref057]\], although both versions appear to perform actin-based motility effectively. An association between neurological melioidosis and strains with *BimA* ~Bm~ was recently reported \[[@pone.0121052.ref055]\]. Severe clinical presentations have been associated with the co-occurrence of *BimA* ~Bm~ and the hemagglutinin, *fhaB3*. The lack of *fhaB3* in isolates exhibiting *BimA* ~Bm~ was correlated with cutaneous melioidosis without sepsis \[[@pone.0121052.ref055]\]. Testing isolates with varied distributions of these virulence components will help corroborate these associations.

The Inv/Mxi-Spa-like type III secretion system (T3SS-3) \[[@pone.0121052.ref058]\] is essential for the survival of *B*. *pseudomallei* in the host \[[@pone.0121052.ref059], [@pone.0121052.ref060]\] and closely resembles secretion systems found in other animal pathogens (*Salmonella* spp. and *Shigella* spp.). *B*. *pseudomallei* isolates 1026b and HBPUB10134a appear to have reduced homology for BPSS1528, which is described as a (HNS-like regulatory) hypothetical protein in the T3SS-3 system. Several proteins act together to form a pore that becomes bound to the host membrane, thus facilitating the delivery of effector proteins \[[@pone.0121052.ref061], [@pone.0121052.ref062]\]. This system is also likely involved in defenses against autophagy by transporting the BopA effector \[[@pone.0121052.ref063], [@pone.0121052.ref064]\]. In this study, we observed sequence homology variation among many of the isolates in the gene, BPSS1629, from the T3SS-2 cluster.

One of the most dramatic differences observed between isolates was from representative genes in the *Yersinia*-like fimbriae (YLF) gene cluster and the BTFC gene cluster. This division is mutually exclusive \[[@pone.0121052.ref054], [@pone.0121052.ref055]\] and it is unclear whether one cluster confers enhanced virulence over the other and no correlations have been identified between gene cluster and disease severity \[[@pone.0121052.ref055]\]. While YLF genes are generally associated with isolates from Thailand \[[@pone.0121052.ref055]\], we found no geographical correlation in the small sample set that we analyzed in the current study ([Fig. 3](#pone.0121052.g003){ref-type="fig"}).

The FDA Animal Rule was set up to identify a set of relevant isolates that could be used in lieu of human clinical trials in the development of effective medical countermeasures against human disease, including melioidosis. The data presented in this study will provide a genomic background to better understand virulence in *B*. *pseudomallei* and may also help in the development of more effective medical countermeasures.
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###### The complete LS-BSR matrix for all coding regions in each genome investigated.
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Click here for additional data file.

###### A NASP (<http://tgennorth.github.io/NASP/>) matrix containing all SNPs from non-duplicated regions from all genomes queried.
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Click here for additional data file.

###### Synteny dot plots between finished genomes available in GenBank and draft genomes generated in this study from re-sequencing studies.

Dot plots were generated using the mummerplot method in MUMmer.

(TIF)
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Click here for additional data file.

###### A Kaplan-Meier curve of survival probabilities based on the BALB/c mice challenge studies conducted in the current study.

The survival probabilities were calculated using the 'survival' package in R \[[@pone.0121052.ref012]\].

(TIF)
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###### Sequencing information for isolates sequenced in the current study.
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###### Accession information for reference genomes.
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###### Virulence associated genes in the current study.
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###### Survival information over the course of BALB/c challenge studies for all strains challenged.
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